In its latest 13F filing, Tweedy Browne Asset Management reported a reduction in its Ionis Pharmaceuticals stake from 3.7 million shares to 2.1 million shares, a decrease of over 40%. The transaction reflects a strategic reprioritization within the value-focused portfolio.

The trimmed position lowered Ionis to approximately 3.8% of the fund’s total equity holdings, down from 6.9% previously. This shift frees capital for investments in other healthcare or technology names favored by the strategy.

Analysts may view the move as a signal of waning conviction in Ionis’s near-term pipeline catalysts. Market response will depend on whether other large holders follow suit or perceive this as a buying opportunity.